Recurrent Pregnancy Loss Clinical Trial
Official title:
Treatment of Recurrent Pregnancy Loss Using Mesenchymal Stem Cells Capable of Differentiation in the Endometrial-decidual Direction
Treatment of Recurrent pregnancy loss using mesenchymal stem cells capable of differentiation in the endometrial-decidual direction.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - female patients of reproductive age 18-49 years; - recurrent pregnancy loss without current pregnancy with thin endometrium; - unsuccessful IVF cycles due to thin endometrium; - endometrial thickness is =6 mm in the first and second phases of the menstrual cycle; - uterine infertility associated with endometrial hypoplasia; - the absence of genetic diseases that prevent pregnancy; - absence of taking hormonal drugs for 3 months prior to enrollment in the study. Exclusion Criteria: - patients with congenital malformations of the genital organs: agenesis and aplasia of the uterus, bicornuate uterus, unicornuate uterus, congenital fistula between the uterus and the digestive and urinary tracts, other congenital anomalies of the body and cervix. congenital anomaly of the body and cervix, unspecified, other specified developmental anomalies; - acute inflammatory processes in the uterus; - acute or chronic infectious and non-infectious diseases in the acute stage, including HIV, hepatitis B and C, syphilis, tuberculosis, chlamydia, myco-, ureaplasmosis, herpes, toxoplasmosis, rubella, cytomegalovirus, gonorrhea, trichomoniasis, etc.; - autoimmune diseases; - patients with malignant tumor including a history; - patients with benign tumors of the uterus and appendages; - miscarriage not associated with a thin endometrium, including immunological origin; - hyper- or hypogonadotropic insufficiency of ovarian function, hyperandrogenemia of any origin; - allergic reactions in the acute stage, established hypersensitivity to any component of the biomedical cell product; - permanent therapy with cytostatics, hormones; - mental and behavioral disorders that make it impossible for patients to participate in the study, drug and/or alcohol addiction. |
Country | Name | City | State |
---|---|---|---|
Belarus | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Minsk |
Lead Sponsor | Collaborator |
---|---|
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian Medical Academy of Post-Graduate Education |
Belarus,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse effects associated with the therapy | Determination of adverse effects associated with the therapy | 1 year | |
Primary | Adverse effects associated with the therapy | Determination of adverse effects associated with the therapy | 1 month | |
Primary | Percent of patients with successful pregnancy | Percent of patients with successful pregnancy within 1 year after treatment | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04718233 -
Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss
|
Phase 2 | |
Recruiting |
NCT01946945 -
Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis
|
Phase 2 | |
Completed |
NCT02572154 -
Sperm DNA Fragmentation in Recurrent Pregnancy Loss
|
N/A | |
Completed |
NCT03174951 -
Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss
|
Phase 2 | |
Recruiting |
NCT05444283 -
Genomic Predictors of Recurrent Pregnancy Loss
|
||
Active, not recruiting |
NCT04621773 -
Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss
|
||
Recruiting |
NCT02990403 -
The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
|
Phase 4 | |
Recruiting |
NCT02990390 -
The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla
|
N/A | |
Not yet recruiting |
NCT05612620 -
Elucidating the Microbiome in Patients With Recurrent Pregnancy Loss
|
||
Suspended |
NCT04397042 -
SCUBE-1 and Carotid Intima Media Thickness in Recurrent Pregnancy Loss
|
||
Not yet recruiting |
NCT05341856 -
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL
|
Early Phase 1 | |
Recruiting |
NCT06007560 -
Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss
|
N/A | |
Completed |
NCT02386384 -
TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure
|
N/A | |
Recruiting |
NCT01635426 -
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages
|
Phase 2/Phase 3 | |
Suspended |
NCT01546350 -
Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH
|
Phase 2 | |
Completed |
NCT00721591 -
Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy
|
N/A | |
Terminated |
NCT00564174 -
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
|
N/A | |
Completed |
NCT04455256 -
Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss
|
||
Not yet recruiting |
NCT05237843 -
Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss
|
Phase 1 | |
Recruiting |
NCT02144064 -
Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin
|
Phase 3 |